Skip to main content

Inclusion Body Myositis

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Syneos Health
Syneos HealthNC - Morrisville
1 program
1
ABC008Phase 2/31 trial
Active Trials
NCT05721573Completed272Est. Nov 2025
Abcuro
AbcuroMA - Newton
1 program
1
ulviprubartPhase 2/3
Biosensics
BiosensicsMA - Newton
1 program
PAMSys pendant PAMSys wrist sensorsN/A1 trial
Active Trials
NCT06153108Active Not Recruiting20Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
Syneos HealthABC008
BiosensicsPAMSys pendant PAMSys wrist sensors

Clinical Trials (2)

Total enrollment: 292 patients across 2 trials

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Start: Feb 2023Est. completion: Nov 2025272 patients
Phase 2/3Completed
NCT06153108BiosensicsPAMSys pendant PAMSys wrist sensors

Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time

Start: Nov 2023Est. completion: Dec 202720 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.